comparemela.com

Latest Breaking News On - Adhish patil - Page 1 : comparemela.com

aarti drugs q1 results: Aarti Drugs shares skyrocket over 19% on Q1 results and buyback announcement

Further, the board has approved a buyback not exceeding 6,65,000 lakh equity shares for an amount not exceeding Rs 59.85 crore. The buyback price is fixed at Rs 900 per equity share, which is a 76% premium from the last closing price.

Aarti Drugs shares zoom 19% to hit one-year high after strong Q1 FY24 results Details here

Aarti Drugs share price: On technical setup, the stock was last seen trading higher than the 5-day, 20-, 50-, 100- and 200-day moving averages. The counter's 14-day relative strength index (RSI) came at 83.71. A level below 30 is defined as oversold while a value above 70 is considered overbought. The company's stock has a price-to-earnings (P/E) ratio of 28.48 against a price-to-book (P/B) value of 4.24.

Aarti Drugs unit gets approval under pharma PLI scheme

Aarti Speciality Chemicals, a wholly-owned subsidiary of Aarti Drugs has received an approval accorded under Production Linked Incentive (PLI) scheme for pharmaceutical sector. Government of India s Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers recently launched a Production Linked Incentive (PLI) scheme to promote domestic manufacturing by incentivising pharmaceutical manufacturers to set-up greenfield projects in India with a minimum domestic value addition in four different target segments (Two in Fermentation based - at least 90% and Two in the Chemical Synthesis based - at least 70%) with a total outlay of Rs 6,940 crore. The objective of the scheme is achieving self-reliance and reducing import dependence in these critical Key Starting Materials (KSMs)/ Drug Intermediates/ Active Pharmaceutical Ingredients (APIs) in the country. The tenure of the scheme is from FY21 to FY30.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.